CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the rec...
Phase 1, Phase 2
Birmingham, Alabama, United States and 104 other locations
to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma...
Phase 2
Birmingham, Alabama, United States and 56 other locations
in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus za...
Phase 3
Birmingham, Alabama, United States and 150 other locations
trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary object...
Phase 1, Phase 2
Birmingham, Alabama, United States and 22 other locations
of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabin...
Phase 1
Birmingham, Alabama, United States and 37 other locations
pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas...
Phase 1, Phase 2
Birmingham, Alabama, United States and 36 other locations
choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy....
Phase 3
Birmingham, Alabama, United States and 159 other locations
This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome...
Phase 2
Birmingham, Alabama, United States and 52 other locations
other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify ...
Phase 1, Phase 2
Birmingham, Alabama, United States and 56 other locations
is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma...
Phase 1
Birmingham, Alabama, United States and 5 other locations
Clinical trials
Research sites
Resources
Legal